Loading
If a patient has had no detectable myeloma for a year or more, stop maintenance and watch, restarting only if disease reappears.
For a patient with multiple myeloma whose disease has been undetectable by MRD testing for a year or more, this idea proposes stopping maintenance and watching, restarting only if disease reappears. The rationale is that sustained MRD negativity at the most sensitive threshold predicts a very low rate of relapse, that MRD re-emergence precedes clinical relapse by months, and that indefinite lenalidomide adds toxicity, second cancers and cost. The hypothesis is that stopping after twelve months of sustained MRD negativity gives non-inferior progression-free survival with better quality of life. PERSEUS, MASTER, DRAMMATIC (SWOG S1803) and GEM2014MAIN test stopping, so it is being tested at scale; it addresses the bottlenecks of dormant cells and minimal residual disease and of trial design.
One of the most cited trial reports Europe PMC returns for Lenalidomide in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Lenalidomide in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Lenalidomide in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares PERSEUS, MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), Newly diagnosed multiple myeloma, transplant-eligible, Daratumumab.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Daratumumab, Lenalidomide, MRD / molecular residual disease testing.
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), Daratumumab, Dormant cells and minimal residual disease, Lenalidomide.
Shares PERSEUS, Newly diagnosed multiple myeloma, transplant-eligible, Daratumumab, Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Daratumumab, Lenalidomide, Multiple myeloma.
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), MRD / molecular residual disease testing, Multiple myeloma.
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), Daratumumab, Lenalidomide, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Daratumumab, Lenalidomide, Multiple myeloma.